Dr. Michael Wechsler
Pulmonary Disease · Denver, CO
CMS Profile ID: 68919 · NPI: 1528017993
F
Payment Grade
High payments ($100,000+). This grade reflects disclosed general payments in CMS Open Payments program year 2024 only.
Total Disclosed Payments
$470,323
Number of Payments
276
Transparency Score
1/5
Payments by Type
| Payment Type | Amount |
|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $197,898 |
| Consulting Fee | $153,908 |
| Travel and Lodging | $114,015 |
| Food and Beverage | $3,950 |
| Grant | $495 |
| Education | $57 |
Top Paying Companies
| Manufacturer / GPO | Amount |
|---|---|
| GlaxoSmithKline, LLC. | $154,373 |
| GENZYME CORPORATION | $101,965 |
| AstraZeneca Pharmaceuticals LP | $96,429 |
| SANOFI-AVENTIS U.S. LLC | $44,382 |
| Regeneron Healthcare Solutions, Inc. | $41,553 |
| Merck Sharp & Dohme LLC | $14,330 |
Top contributing companies shown; smaller payers may be omitted.
These totals are computed from the official CMS Open Payments program-year 2024 general-payment
file. To see the full, authoritative record for this provider — including research payments and
line-item detail — look them up by name or NPI on the
official CMS Open Payments portal.
What should I ask my doctor?
- Are you a paid speaker or consultant for any pharmaceutical or device company?
- Do any of your prescribing choices reflect relationships with industry?
- Is there an equivalent generic or alternative treatment?